Annual Report · 10-K
Adicet Bio, Inc.
ACETNASDAQEQUITYCurrent
Annual Report
Company context
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗